{"title":"Association between Air Quality Index and the risk of rosacea: a nationwide population-based cohort study.","authors":"Sheng-Hsiang Ma, Chun-Ying Wu, Meng-Chieh Li, Hsiu J Ho, Chon-Kit Ao, Chen-Yi Wu","doi":"10.1093/ced/llae291","DOIUrl":"10.1093/ced/llae291","url":null,"abstract":"<p><strong>Background: </strong>Air pollution is associated with several inflammatory skin disorders. However, the association between air quality and rosacea remains unclear.</p><p><strong>Objectives: </strong>To investigate the association between the Air Quality Index (AQI) and incidence of rosacea.</p><p><strong>Methods: </strong>In total, 21 709 479 participants without rosacea before 2008 were recruited from the Taiwan National Health Insurance Research Database. The long-term average AQI value for each participant was acquired from the Taiwan Air Quality Monitoring System Network and calculated from 1 January 2008 until the diagnosis of rosacea, withdrawal from the National Health Insurance programme, or 31 December 2018.</p><p><strong>Results: </strong>We observed a significant association between AQI and the incidence of rosacea, with each unit elevation in the AQI increasing the risk of rosacea by 5%. We then categorized participants equally into four groups by quantiles (Q) of AQI values, with mean AQI values of: Q1, 69.0 (SD 6.4); Q2, 79.0 (SD 2.3); Q3, 89.9 (SD 3.6); and Q4, 103.9 (SD 6.8). Compared with the Q1 group, the Q2, Q3 and Q4 cohorts exhibited 1.82-fold, 4.48-fold and 7.22-fold increased risk of rosacea, respectively. Additionally, exposure to particulate matter (PM)2.5 (airborne particulate matter with a diameter ≤ 2.5 μm), sulfur dioxide (SO2) and carbon monoxide increased the risk of rosacea, whereas exposure to PM10 (airborne PM with a diameter ≤ 10 μm) was associated with a lower risk.</p><p><strong>Conclusions: </strong>This study supported a significant dose-response relationship between AQI and the incidence of rosacea.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"69-76"},"PeriodicalIF":3.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Niccolò Gori, Andrea Chiricozzi, Stefania Sfregola, Elena Ippoliti, Alessandro Di Stefani, Dalma Malvaso, Lucia Di Nardo, Francesco Federico, Gian Franco Zannoni, Ketty Peris
{"title":"Histological features of immune cell infiltrate in lesional skin correlate with therapeutic response to dupilumab.","authors":"Niccolò Gori, Andrea Chiricozzi, Stefania Sfregola, Elena Ippoliti, Alessandro Di Stefani, Dalma Malvaso, Lucia Di Nardo, Francesco Federico, Gian Franco Zannoni, Ketty Peris","doi":"10.1093/ced/llae321","DOIUrl":"10.1093/ced/llae321","url":null,"abstract":"<p><p>Over the past decade, dupilumab, a monoclonal human antibody that inhibits interleukin (IL)-4 and IL-13 signalling, has revolutionized the therapeutic management of moderate-to-severe atopic dermatitis (AD), facilitating long-term control of its signs and symptoms. The aim of this study was to identify histological predictors of the efficacy of dupilumab after 16 weeks of treatment in a cohort of 40 adults with moderate-to-severe AD who had undergone a skin biopsy for diagnostic purposes before treatment initiation. We found that Eczema Area and Severity Index (EASI) 75 and EASI 90 responses at week 16 were significantly associated with perivascular localization [odds ratio (OR) 17.6; P = 0.04] and lichenoid distribution (OR 31.8; P = 0.03) of the immune infiltrate. Moreover, for each unit increase in the number (cells mm-2) of CD4+ cells, the likelihood of achieving an EASI 75 response decreased by 1% (OR 0.99; P = 0.04). In conclusion, our study found promising pretreatment immunohistochemical markers that could predict how well patients with AD respond to dupilumab.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"134-136"},"PeriodicalIF":3.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laksha Bala, Khawar Hussain, Rashmi Shetty, Neil P Patel
{"title":"Pembrolizumab-induced hypertrophic lichenoid dermatitis with involvement of an old tattoo.","authors":"Laksha Bala, Khawar Hussain, Rashmi Shetty, Neil P Patel","doi":"10.1093/ced/llae345","DOIUrl":"10.1093/ced/llae345","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"176-178"},"PeriodicalIF":3.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antonio Alma, Francesca Beretti, Cecilia Bonilauri, Johanna Chester, Shaniko Kaleci, Silvana Ciardo, Laura Bertoni, Giovanni Pellacani, Francesca Farnetani
{"title":"Atypical naevi in dermoscopy and reflectance confocal microscopy: correlation between immunohistochemistry and diagnostic patterns of atypia.","authors":"Antonio Alma, Francesca Beretti, Cecilia Bonilauri, Johanna Chester, Shaniko Kaleci, Silvana Ciardo, Laura Bertoni, Giovanni Pellacani, Francesca Farnetani","doi":"10.1093/ced/llae326","DOIUrl":"10.1093/ced/llae326","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"172-174"},"PeriodicalIF":3.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rodrigo Peñuelas Leal, Carolina Labrandero Hoyos, Jose Amancio Peñuelas Ruiz, Leticia Bagán, Violeta Zaragoza Ninet, Jose Luis Sánchez Carazo, Gemma Pérez Pastor, Andrés Grau Echevarría, Altea Esteve Martínez, Malena Finello, Daniel Blaya Imbernon, Víctor Dios Guillán, Lucía Aguilar González, José Bagán, Victor Alegre De Miquel
{"title":"Treatment of Behçet disease with oral roflumilast: an observational study.","authors":"Rodrigo Peñuelas Leal, Carolina Labrandero Hoyos, Jose Amancio Peñuelas Ruiz, Leticia Bagán, Violeta Zaragoza Ninet, Jose Luis Sánchez Carazo, Gemma Pérez Pastor, Andrés Grau Echevarría, Altea Esteve Martínez, Malena Finello, Daniel Blaya Imbernon, Víctor Dios Guillán, Lucía Aguilar González, José Bagán, Victor Alegre De Miquel","doi":"10.1093/ced/llae284","DOIUrl":"10.1093/ced/llae284","url":null,"abstract":"<p><strong>Background: </strong>Mucocutaneous Behçet disease often presents a therapeutic challenge. Roflumilast has shown promise in the treatment of other inflammatory dermatological conditions.</p><p><strong>Objectives: </strong>The objective of this study was to evaluate the characteristics, effectiveness and safety of roflumilast in the treatment of Behçet disease-associated aphthosis in routine clinical practice.</p><p><strong>Methods: </strong>We performed a single-cohort ambispective observational study. Eleven patients with Behçet disease treated with roflumilast participated. Data collection included demographic, clinical and outcome variables. Statistical analysis compared 12 weeks of treatment with roflumilast with a previous period without treatment and with a period when the previous treatment was used.</p><p><strong>Results: </strong>During treatment with roflumilast, a reduction in flare-ups and oral ulcers was observed compared with the untreated period and the previous treatment period. A reduction in genital ulcers, pain and ulcer duration was observed between the without treatment period and the roflumilast treatment period. Adverse effects occurred in 54% of patients, most of which were self-limiting or manageable with dose adjustment. No patients withdrew treatment.</p><p><strong>Conclusions: </strong>Roflumilast appears to be a potential option in the treatment of Behçet disease with favourable effectiveness, safety and tolerability profiles. Although further research is needed, roflumilast offers a promising treatment option for Behçet disease-associated aphthosis, which could improve the patients' quality of life and address unmet therapeutic needs.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"62-68"},"PeriodicalIF":3.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141757492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chng Wei Qiang, Benjamin Ho Wen Yang, Wang Shi, Lim Kok Hing, Laura Hui Li Yao
{"title":"An unusual cause of erythroderma.","authors":"Chng Wei Qiang, Benjamin Ho Wen Yang, Wang Shi, Lim Kok Hing, Laura Hui Li Yao","doi":"10.1093/ced/llae392","DOIUrl":"10.1093/ced/llae392","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"227-230"},"PeriodicalIF":3.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rayad B Shams, Philip M McDaniel, Karyn B Stitzenberg, Christopher J Sayed
{"title":"Social determinants of health and hidradenitis suppurativa disease severity: a geocoded analysis.","authors":"Rayad B Shams, Philip M McDaniel, Karyn B Stitzenberg, Christopher J Sayed","doi":"10.1093/ced/llae299","DOIUrl":"10.1093/ced/llae299","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"150-151"},"PeriodicalIF":3.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Treatment of Hailey-Hailey disease with biologics and small-molecule inhibitors: a systematic review.","authors":"Wei Liu, Xiao Xue, Shanshan Li","doi":"10.1093/ced/llae298","DOIUrl":"10.1093/ced/llae298","url":null,"abstract":"<p><p>Hailey-Hailey disease (HHD) is a rare genetic dermatosis characterized by recurrent flaccid vesicles and blisters on erythematous skin in friction areas. The disease follows a chronic relapsing course and has a significant psychological and social impact. Currently, there is no standardized therapeutic regimen for HHD, posing a challenge for dermatologists in managing the condition. We performed this systematic review to investigate the therapeutic role of biologics and small-molecule inhibitors in the treatment of HHD. A systematic search was conducted of the PubMed, Embase, Web of Science, Scopus and Cochrane databases from inception to 1 January 2024. In total, 31 patients with HHD from 18 articles were included in the analysis. Biologics and small-molecule inhibitors were evaluated, including dupilumab, apremilast, upadacitinib, abrocitinib, adalimumab and etanercept. Most reported cases demonstrated clinical improvement after treatment initiation, with few major adverse events. However, some patients experienced recurrences. In conclusion, biologics and small-molecule inhibitors may offer a treatment alternative for patients with refractory HHD, but further confirmation is necessary through large-scale randomized controlled clinical trials.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"38-45"},"PeriodicalIF":3.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Viral infections in atopic dermatitis.","authors":"Nada Khalil, Joshua Walton, Nerys Roberts, Khawar Hussain","doi":"10.1093/ced/llae304","DOIUrl":"10.1093/ced/llae304","url":null,"abstract":"<p><p>Individuals with atopic dermatitis are susceptible to frequent viral skin infections due to compromised epidermal barrier function and immune dysregulation. The diagnosis and management of viral infections in atopic dermatitis can be challenging due to various clinical phenotypes and overlapping clinical features. We reviewed the literature for the diagnosis, aetiology, management, differential diagnoses and complications of these viral infections to provide an up-to-date clinical overview for clinicians involved in caring for patients with atopic dermatitis, including features specific to patients with skin of colour. Accurate diagnosis and appropriate management in cases of uncertainty are crucial due to the risk of life-threatening complications with some viral infections. The differing presentations of these infections in patients with skin of colour are highlighted, as this is an underrepresented area of research. Future research with greater diversity of patients is needed for patients with atopic dermatitis complicated by viral skin infections.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"46-55"},"PeriodicalIF":3.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}